Gonzalez Izundegui, Daniel
Miller, Patricia E.
Shah, Ravi V.
Clish, Clary B.
Walker, Maura E.
Mitchell, Gary F.
Gerszten, Robert E.
Larson, Martin G.
Vasan, Ramachandran S.
Nayor, Matthew
Funding for this research was provided by:
National Institutes of Health
Article History
Received: 12 July 2022
Accepted: 29 September 2022
First Online: 15 October 2022
Declarations
:
: The study was approved by the Institutional Review Board at Boston University Medical Campus/Boston Medical Center and all participants provided written informed consent.
: Not applicable.
: In the past 12 months, Dr. Shah has served as a consultant for Myokardia (ongoing) and Best Doctors (ongoing), receives research funding from Amgen (concluded), had minor stock holdings in Gilead, and his spouse has current stock holdings in Pfizer. Dr. Shah is a co-inventor on a patent for ex-RNAs signatures of cardiac remodeling. Dr. Mitchell is owner of Cardiovascular Engineering, Inc., a company that designs and manufactures devices that measure vascular stiffness. The company uses these devices in clinical trials that evaluate the effects of diseases and interventions on vascular stiffness. Dr. Mitchell also serves as a consultant to and receives grants and honoraria from Novartis, Merck, Bayer, Servier, Philips and deCODE genetics. Dr. Nayor has served as a guest speaker/consultant for Cytokinetics. All other authors have no competing interests to declare.